^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | CI-1040 (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
Excerpt:
NSCLC lines of known genetic backgrounds (Table 1) were treated with the MEK inhibitor CI-1040. Figure 2A shows that the LKB1/KRAS mutant cell lines have a uniform enhanced sensitivity to CI-1040 when compared with wild-type cell lines, LKB1 mutant lines or KRAS mutant lines (labelled control cell lines in Figure 2B)...The mean relative proliferation rate calculated for LKB1/KRAS mutant cell lines, and compared with the control cell line cluster was statistically significant (P<0.001 at all CI-1040 concentrations >0; Figure 2B). LKB1/KRAS mutant cell lines have a mean IC50 value of 5 μ M compared with the control cell lines, which have a mean IC50>10 μ M. ..
